Novartis AG ADR (NVS)vsPhreesia Inc (PHR)
NVS
Novartis AG ADR
$145.23
-0.55%
HEALTHCARE · Cap: $277.42B
PHR
Phreesia Inc
$9.57
-5.90%
HEALTHCARE · Cap: $581.50M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 11673% more annual revenue ($56.58B vs $480.59M). NVS leads profitability with a 23.9% profit margin vs 0.5%. NVS trades at a lower P/E of 20.8x. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PHR
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-51.8%
Fair Value
$110.12
Current Price
$145.23
$35.11 premium
Margin of Safety
+77.8%
Fair Value
$56.21
Current Price
$9.57
$46.64 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
15.9% revenue growth
Areas to Watch
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.8% — below average capital efficiency
0.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PHR
The strongest argument for PHR centers on Price/Book, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Bear Case : PHR
The primary concerns for PHR are EPS Growth, Market Cap, Return on Equity. A P/E of 239.3x leaves little room for execution misses. Thin 0.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS profiles as a declining stock while PHR is a growth play — different risk/reward profiles.
PHR carries more volatility with a beta of 0.89 — expect wider price swings.
PHR is growing revenue faster at 15.9% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 43/100), backed by strong 23.9% margins. PHR offers better value entry with a 77.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Phreesia Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Phreesia, Inc. provides integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company is headquartered in Raleigh, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?